Modified poly-L-lysine for use as a clearing agent in pretargeted radioimmunotherapy
Modified poly-L-lysine for use as a clearing agent in pretargeted radioimmunotherapy
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Background
Pretargeted radioimmunotherapy of cancer has the potential to increase tumor specific uptake of activity when compared with conventional radioimmunotherapy. This is especially true in radioimmunotherapy with nuclides that exhibit a relatively short half-life. When administering antibody-based pretargeting molecules systemically, the a...
Alternative Titles
Full title
Modified poly-L-lysine for use as a clearing agent in pretargeted radioimmunotherapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_cabb03c8fd074292a9d3e50505dd36cf
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_cabb03c8fd074292a9d3e50505dd36cf
Other Identifiers
ISSN
2365-421X
E-ISSN
2365-421X
DOI
10.1186/s41181-024-00307-6
